BioSpace News Archive

RxLightning today announced that it closed a $17.5 million Series A investment to support the company’s growth and further remove barriers to life-saving therapies.

Intensity Therapeutics, Inc. today announced that data from its INVINCIBLE study was presented on June 4, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, announced its support for the sixth International NASH Day, taking place on June 8, 2023.

Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, provides a corporate update on a series of advancements for the company, including the completion of its reverse merger earlier this month in an all-stock transaction.

aTyr Pharma, Inc. today announced multiple presentations at the International Union of Biochemistry and Molecular Biology’s 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to take place June 4 – 9 in Ontario, Canada.

Bionano Genomics, Inc. announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded and tumor tissue.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, recently hosted Congressman Scott Peters for a tour of the RNA manufacturing facility at Wateridge Circle in San Diego.

AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced the establishment of a joint clinical collaboration agreement with University Hospitals.

Brain–computer interface company Precision Neuroscience Corporation announced that the first-in-human procedures in a pilot clinical study of its neural implant system have been successfully completed.

XORTX Therapeutics Inc. is pleased to announce presentation of scientific data underpinning the recent Orphan Drug Designation (“ ODD ”) at the PKD Foundation – “PKD Connect” meeting being held June 22-24, 2023 in Denver, Colorado.